New Users Registration  |  Useful Links  |  FAQ  |  Site Map 
 
Go Search

 

Skip Navigation LinksHealth Xchange > News
  News  
  Categories  
     
  Chronology  
 
  2013 2014   Dec 2014 | Nov 2014 | Oct 2014 | Sep 2014 | Aug 2014 | Jul 2014 | Jun 2014 | May 2014 | Apr 2014 | Mar 2014 | Feb 2014 | Jan 2014 |
  2013   Dec 2013 | Nov 2013 | Oct 2013 | Sep 2013 | Aug 2013 | Jul 2013 | Jun 2013 | May 2013 | Apr 2013 | Mar 2013 | Feb 2013 | Jan 2013 |
  2012   Dec 2012 | Nov 2012 | Oct 2012 | Sep 2012 | Aug 2012 | Jul 2012Jun 2012May 2012Apr 2012Mar 2012 | Feb 2012 | Jan 2012 |
  2011   Dec 2011Nov 2011Oct 2011 | Sep 2011 | Aug 2011Jul 2011Jun 2011 | May 2011 | Apr 2011 | Mar 2011 | Feb 2011 | Jan 2011 |
  2010   Dec 2010 | Nov 2010 | Oct 2010 | Sep 2010 | Aug 2010 | Jul 2010 | Jun 2010 | May 2010 | Apr 2010 | Mar 2010 | Feb 2010 | Jan 2010 |
  2009   Dec 2009 | Nov 2009 | Oct 2009 | Sep 2009 | Aug 2009 |
 
     
  Topic  
 
  Health Policy and Announcements | Diseases and Outbreaks
  Medical Research | New Treatments and Technology
   
 
     
  RSS  
 
  Singapore   SingHealth | Health Promotion Board | Ministry of Health | Asiaone
  International   World Health Organization | Centre for Disease Control and Prevention (US)
       
 
     
  News Article  
 

 S’pore, US firms in pandemic flu vaccine tie-up

 
  Saturday, 28 l 08 l 2010 Source: The Straits Times   
By: Grace Chua
     
 

TEMASEK Life Sciences Ventures (TLV) this month announced a joint venture to develop a pandemic flu vaccine with a United States biotech firm.

TLV, the commercialisation arm of Temasek Life Sciences Laboratories, will work with Maryland-deadquartered Emergent BioSolutions to develop, manufacture and commercialise the flu vaccine.

The vaccine will target a number of H5 influenza strains, which circulate in bird populations like poultry and can be transmitted to humans.

In particular, the H5N1 flu virus has been singled out as a potential pandemic if it mutates to spread easily from person to person. Sixty per cent of people infected by the virus do not survive.

The Singapore-based joint venture, called EPIC BIO, aims to begin manufacturing next year and start clinical trials in 2012.

On the basic research front, Temasek Life Sciences Laboratories last week signed a memorandum of
understanding with Japan’s National Institute for Basic Biology for a five-year tie-up to study plants and animals.

The institutes will conduct joint research, host visiting researchers and graduate exchange students, and focus on projects involving model organisms such as fruit flies and zebrafish.

     
  Ask the Specialists - Free Doctor Q&A
(Now - 30 Apr)
 
    Feet Problems
If you have questions related to feet problems, take this opportunity to get valuable advice from a podiatrist -- now!
 
    Previous Q&As
Check out our archive for all our previous doctor's Q&As!
*Latest Update: Age-related Eye Conditions (Cataract, Glaucoma, Diabetic Retinopathy), All About Medication
 
  Medical Expertise Contributed by:  
  Singapore General Hospital
Tel: (65) 6222 3322
 
  KK Women's and Children's Hospital
Tel:(65) 6225 5554
 
  National Cancer Centre Singapore
Tel: (65) 6436 8000
 
  National Heart Centre Singapore
Tel: (65) 6436 7800
 
  Singapore National Eye Centre
Tel: (65) 6227 7255
 
  National Dental Centre Singapore
Tel: (65) 6324 8910
 
  National Neuroscience Institute
Tel: (65) 6357 7153
 
SingHealth Polyclinics
Tel: (65) 6236 4800